Summary of findings: nonutility results for diagnostic management
| Health state/outcome (categories of values and preferences) . | Estimates . | Certainty in evidence . |
|---|---|---|
| No. of participants/studies . | ||
| Prophylaxis | ||
| Thrombophilia testing preferences (van Korlaar et al61 ) | Participants, members of families with heritable protein C deficiency who had not been tested before, were quite interested in getting a genetic test for protein C deficiency (mean, 4.6; standard deviation, 2.4 (on a scale from 1 to 7), with that decision being primarily a matter of concern for the family. | ⊕⊕○○ Low certainty due to serious RoB* and imprecision† |
| 168 participants from 1 cross-sectional study | ||
| Treatment | ||
| Diagnostic management preferences: false-negative results (Geyer et al48 ) | The majority (63%) of patients favored undergoing CTPA in a low pretest probability scenario. The most common cited factors for declining the test were risk of radiation-associated malignancy, contrast-induced nephropathy, or allergy. Others deferred CTPA testing because they believed it was unnecessary; however, patients with a previous PE diagnosis were less likely to defer CTPA. Most patients (85%) who accepted CTPA testing had concerns about missing a PE. | ⊕⊕⊕⊕ High certainty |
| 203 participants from 1 cross-sectional study |
| Health state/outcome (categories of values and preferences) . | Estimates . | Certainty in evidence . |
|---|---|---|
| No. of participants/studies . | ||
| Prophylaxis | ||
| Thrombophilia testing preferences (van Korlaar et al61 ) | Participants, members of families with heritable protein C deficiency who had not been tested before, were quite interested in getting a genetic test for protein C deficiency (mean, 4.6; standard deviation, 2.4 (on a scale from 1 to 7), with that decision being primarily a matter of concern for the family. | ⊕⊕○○ Low certainty due to serious RoB* and imprecision† |
| 168 participants from 1 cross-sectional study | ||
| Treatment | ||
| Diagnostic management preferences: false-negative results (Geyer et al48 ) | The majority (63%) of patients favored undergoing CTPA in a low pretest probability scenario. The most common cited factors for declining the test were risk of radiation-associated malignancy, contrast-induced nephropathy, or allergy. Others deferred CTPA testing because they believed it was unnecessary; however, patients with a previous PE diagnosis were less likely to defer CTPA. Most patients (85%) who accepted CTPA testing had concerns about missing a PE. | ⊕⊕⊕⊕ High certainty |
| 203 participants from 1 cross-sectional study |
High certainty in evidence: We are very confident that the true effect lies close to that of the estimate of the effect. Low certainty in evidence: Our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.
CTPA, computed tomography pulmonary angiography.
van Korlaar et al61 was a study with unclear sampling methods, risk of measurement of instrument, and health state presentations.
Estimation referring to a subgroup of 76 participants who had not been previously tested.